10-K Filing

BNB PLUS CORP. CIK: 744452 FY 2019

Filing Information

Form Type	10-K
Accession Number	`0001104659-19-072186`
Period End Date	20190930
Filing Date	20191212
Fiscal Year	2019
Fiscal Period	FY
XBRL Instance	apdn-20190930.xml

Filing Contents

This filing contains the following financial statements:

Balance Sheet 74 Income Statement 42 Cash Flow Statement 72 Stockholders Equity 22

Balance Sheet 74 line items

Line Item	Tag	Value	Unit	Period
Allowance on accounts receivable (in dollars)	`AllowanceForDoubtfulAccountsReceivableCurrent`	$13.13K	USD	Point-in-time
Allowance on accounts receivable (in dollars)	`AllowanceForDoubtfulAccountsReceivableCurrent`	$4.50K	USD	Point-in-time
Accounts payable and accrued liabilities, related parties (in dollars)	`AccountsPayableRelatedPartiesCurrentAndNoncurrent`	$5.84K	USD	Point-in-time
Convertible notes payable, related parties (in dollars)	`NotesPayableRelatedPartiesNoncurrent`	$1.14M	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$558.99K	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$1.66M	USD	Point-in-time
Preferred stock, par value (in dollars per share)	`PreferredStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Preferred stock, par value (in dollars per share)	`PreferredStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Accounts receivable, net of allowance of $4,500 and $13,133 at September 30, 2019 and 2018, respectively	`AccountsReceivableNetCurrent`	$839.95K	USD	Point-in-time
Accounts receivable, net of allowance of $4,500 and $13,133 at September 30, 2019 and 2018, respectively	`AccountsReceivableNetCurrent`	$1.49M	USD	Point-in-time
Inventories	`InventoryNet`	$221.37K	USD	Point-in-time
Preferred stock, shares authorized	`PreferredStockSharesAuthorized`	10.00M	shares	Point-in-time
Preferred stock, shares authorized	`PreferredStockSharesAuthorized`	10.00M	shares	Point-in-time
Inventories	`InventoryNet`	$142.63K	USD	Point-in-time
Preferred stock, shares issued	`PreferredStockSharesIssued`	0.00	shares	Point-in-time
Preferred stock, shares issued	`PreferredStockSharesIssued`	0.00	shares	Point-in-time
Prepaid expenses and other current assets	`PrepaidExpenseAndOtherAssetsCurrent`	$635.17K	USD	Point-in-time
Prepaid expenses and other current assets	`PrepaidExpenseAndOtherAssetsCurrent`	$604.74K	USD	Point-in-time
Preferred stock, shares outstanding	`PreferredStockSharesOutstanding`	0.00	shares	Point-in-time
Total current assets	`AssetsCurrent`	$2.15M	USD	Point-in-time
Total current assets	`AssetsCurrent`	$4.00M	USD	Point-in-time
Preferred stock, shares outstanding	`PreferredStockSharesOutstanding`	0.00	shares	Point-in-time
Property and equipment, net	`PropertyPlantAndEquipmentNet`	$226.22K	USD	Point-in-time
Common stock, par value	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Property and equipment, net	`PropertyPlantAndEquipmentNet`	$419.77K	USD	Point-in-time
Common stock, par value	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Common stock, shares authorized	`CommonStockSharesAuthorized`	500.00M	shares	Point-in-time
Common stock, shares authorized	`CommonStockSharesAuthorized`	500.00M	shares	Point-in-time
Common stock, shares issued	`CommonStockSharesIssued`	752,802.00	shares	Point-in-time
Common stock, shares issued	`CommonStockSharesIssued`	1.20M	shares	Point-in-time
Deferred offering costs	`DeferredCosts`	$109.70K	USD	Point-in-time
Deferred offering costs	`DeferredCosts`	-	USD	Point-in-time
Common stock, shares outstanding	`CommonStockSharesOutstanding`	1.20M	shares	Point-in-time
Common stock, shares outstanding	`CommonStockSharesOutstanding`	752,802.00	shares	Point-in-time
Deposits	`DepositsAssetsNoncurrent`	$62.35K	USD	Point-in-time
Deposits	`DepositsAssetsNoncurrent`	$62.33K	USD	Point-in-time
Goodwill	`Goodwill`	$285.39K	USD	Point-in-time
Goodwill	`Goodwill`	$285.39K	USD	Point-in-time
Intangible assets, net	`FiniteLivedIntangibleAssetsNet`	$864.20K	USD	Point-in-time
Intangible assets, net	`FiniteLivedIntangibleAssetsNet`	$734.77K	USD	Point-in-time
Total Assets	`Assets`	$3.56M	USD	Point-in-time
Total Assets	`Assets`	$5.63M	USD	Point-in-time
Accounts payable and accrued liabilities (including related party of $5,844 at September 30, 2018)	`AccountsPayableAndAccruedLiabilitiesCurrent`	$1.62M	USD	Point-in-time
Accounts payable and accrued liabilities (including related party of $5,844 at September 30, 2018)	`AccountsPayableAndAccruedLiabilitiesCurrent`	$965.17K	USD	Point-in-time
Deferred revenue	`ContractWithCustomerLiabilityCurrent`	$628.99K	USD	Point-in-time
Deferred revenue	`ContractWithCustomerLiabilityCurrent`	$1.86M	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$2.82M	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$2.25M	USD	Point-in-time
Long term accrued liabilities	`AccountsPayableAndAccruedLiabilitiesNoncurrent`	$621.97K	USD	Point-in-time
Long term accrued liabilities	`AccountsPayableAndAccruedLiabilitiesNoncurrent`	$470.74K	USD	Point-in-time
Secured convertible notes payable, net of debt issuance costs (including related party of $1,139,490 at September 30, 2018)	`ConvertibleLongTermNotesPayable`	$1.59M	USD	Point-in-time
Secured convertible notes payable, net of debt issuance costs (including related party of $1,139,490 at September 30, 2018)	`ConvertibleLongTermNotesPayable`	$1.44M	USD	Point-in-time
Secured convertible notes payable, recorded at fair value	`SecuredConvertibleNotesPayableNoncurrentFairValueDisclosures`	$102.78K	USD	Point-in-time
Total liabilities	`Liabilities`	$4.41M	USD	Point-in-time
Total liabilities	`Liabilities`	$4.88M	USD	Point-in-time
Commitments and contingencies	`CommitmentsAndContingencies`	-	USD	Point-in-time
Commitments and contingencies	`CommitmentsAndContingencies`	-	USD	Point-in-time
Preferred stock, par value $0.001 per share; 10,000,000 shares authorized; -0 shares issued and outstanding as of September 30, 2019 and 2018	`PreferredStockValue`	-	USD	Point-in-time
Preferred stock, par value $0.001 per share; 10,000,000 shares authorized; -0 shares issued and outstanding as of September 30, 2019 and 2018	`PreferredStockValue`	-	USD	Point-in-time
Common stock, par value $0.001 per share; 500,000,000 shares authorized; 35,612,057 and 30,112,057 shares issued and outstanding as of December 31, 2018 and September 30, 2018, respectively	`CommonStockValue`	$1.20K	USD	Point-in-time
Common stock, par value $0.001 per share; 500,000,000 shares authorized; 35,612,057 and 30,112,057 shares issued and outstanding as of December 31, 2018 and September 30, 2018, respectively	`CommonStockValue`	$753.00	USD	Point-in-time
Additional paid in capital	`AdditionalPaidInCapitalCommonStock`	$255.96M	USD	Point-in-time
Additional paid in capital	`AdditionalPaidInCapitalCommonStock`	$249.12M	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-248.37M	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-256.81M	USD	Point-in-time
Applied DNA Sciences, Inc.'s stockholders' (deficit) equity	`StockholdersEquity`	$754.50K	USD	Point-in-time
Applied DNA Sciences, Inc.'s stockholders' (deficit) equity	`StockholdersEquity`	$-841.46K	USD	Point-in-time
Noncontrolling interest	`MinorityInterest`	$-7.04K	USD	Point-in-time
Noncontrolling interest	`MinorityInterest`	-	USD	Point-in-time
Total (deficit) equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$6.86M	USD	Point-in-time
Total (deficit) equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$754.50K	USD	Point-in-time
Total (deficit) equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$-848.50K	USD	Point-in-time
Total Liabilities and (Deficit) Equity	`LiabilitiesAndStockholdersEquity`	$3.56M	USD	Point-in-time
Total Liabilities and (Deficit) Equity	`LiabilitiesAndStockholdersEquity`	$5.63M	USD	Point-in-time

Income Statement 42 line items

Line Item	Tag	Value	Unit	Period
Interest (expense) income, related party interest	`InterestIncomeRelatedParty`	$5.84K	USD	Annual
Interest (expense) income, related party interest	`InterestIncomeRelatedParty`	$46.59K	USD	Annual
Total revenues	`RevenueFromContractWithCustomerIncludingAssessedTax`	$5.39M	USD	Annual
Total revenues	`RevenueFromContractWithCustomerIncludingAssessedTax`	$3.90M	USD	Annual
Cost of revenues	`CostOfRevenue`	$877.61K	USD	Annual
Cost of revenues	`CostOfRevenue`	$1.21M	USD	Annual
Selling, general and administrative	`SellingGeneralAndAdministrativeExpense`	$10.28M	USD	Annual
Selling, general and administrative	`SellingGeneralAndAdministrativeExpense`	$11.04M	USD	Annual
Research and development	`ResearchAndDevelopmentExpense`	$2.75M	USD	Annual
Research and development	`ResearchAndDevelopmentExpense`	$2.97M	USD	Annual
Depreciation and amortization	`DepreciationAndAmortization`	$390.42K	USD	Annual
Depreciation and amortization	`DepreciationAndAmortization`	$547.80K	USD	Annual
Total operating expenses	`OperatingExpenses`	$14.34M	USD	Annual
Total operating expenses	`OperatingExpenses`	$13.64M	USD	Annual
LOSS FROM OPERATIONS	`OperatingIncomeLoss`	$-11.65M	USD	Annual
LOSS FROM OPERATIONS	`OperatingIncomeLoss`	$-9.12M	USD	Annual
Interest (expense) income, net (including related party interest of $46,586 and $5,844 for the years ended September 30, 2019 and 2018, respectively)	`InterestIncomeExpenseNet`	$-162.43K	USD	Annual
Interest (expense) income, net (including related party interest of $46,586 and $5,844 for the years ended September 30, 2019 and 2018, respectively)	`InterestIncomeExpenseNet`	$-9.62K	USD	Annual
Other expense, net	`OtherNonoperatingIncomeExpense`	$-43.30K	USD	Annual
Other expense, net	`OtherNonoperatingIncomeExpense`	$-37.01K	USD	Annual
Loss on extinguishment of debt	`GainsLossesOnExtinguishmentOfDebt`	-	USD	Annual
Loss on extinguishment of debt	`GainsLossesOnExtinguishmentOfDebt`	$-1.26M	USD	Annual
Unrealized gain on change in fair value of secured convertible notes payable	`ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1`	-	USD	Annual
Unrealized gain on change in fair value of secured convertible notes payable	`ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1`	$1.97M	USD	Annual
Loss before provision for income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$-11.69M	USD	Annual
Loss before provision for income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$-8.62M	USD	Annual
Provision for income taxes	`IncomeTaxExpenseBenefit`	$15.00K	USD	Annual
Provision for income taxes	`IncomeTaxExpenseBenefit`	-	USD	Annual
NET LOSS	`ProfitLoss`	$-8.63M	USD	Annual
NET LOSS	`ProfitLoss`	$-11.69M	USD	Annual
Less: Net loss attributable to noncontrolling interest	`NetIncomeLossAttributableToNoncontrollingInterest`	$-9.32K	USD	Annual
Less: Net loss attributable to noncontrolling interest	`NetIncomeLossAttributableToNoncontrollingInterest`	-	USD	Annual
NET LOSS attributable to Applied DNA Sciences, Inc.	`NetIncomeLoss`	$-11.69M	USD	Annual
NET LOSS attributable to Applied DNA Sciences, Inc.	`NetIncomeLoss`	$-8.62M	USD	Annual
Deemed dividend related to warrant modifications	`DeemedDividendRelatedToWarrantModifications`	-	USD	Annual
Deemed dividend related to warrant modifications	`DeemedDividendRelatedToWarrantModifications`	$-309.61K	USD	Annual
NET LOSS applicable to common stockholders	`NetIncomeLossAvailableToCommonStockholdersBasic`	$-11.69M	USD	Annual
NET LOSS applicable to common stockholders	`NetIncomeLossAvailableToCommonStockholdersBasic`	$-8.93M	USD	Annual
Net loss per share applicable to common stockholders-basic and diluted	`EarningsPerShareBasicAndDiluted`	$-9.69	USD	Annual
Net loss per share applicable to common stockholders-basic and diluted	`EarningsPerShareBasicAndDiluted`	$-15.86	USD	Annual
Weighted average shares outstanding-basic and diluted (in shares)	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	921,809.00	shares	Annual
Weighted average shares outstanding-basic and diluted (in shares)	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	737,441.00	shares	Annual

Cash Flow Statement 72 line items

Line Item	Tag	Value	Unit	Period
Proceeds from senior convertible notes payable, related party	`ProceedsFromRelatedPartyDebt`	$1.19M	USD	Annual
Proceeds from senior convertible notes payable, related party	`ProceedsFromRelatedPartyDebt`	$550.00K	USD	Annual
Net loss	`ProfitLoss`	$-8.63M	USD	Annual
Net loss	`ProfitLoss`	$-11.69M	USD	Annual
Interest paid in kind, related party	`PaidInKindInterestRelatedParty`	$98.75K	USD	Annual
Interest paid in kind, related party	`PaidInKindInterestRelatedParty`	$98.75K	USD	Annual
Depreciation and amortization	`DepreciationDepletionAndAmortization`	$547.80K	USD	Annual
Depreciation and amortization	`DepreciationDepletionAndAmortization`	$390.42K	USD	Annual
Loss on extinguishment of debt	`GainsLossesOnExtinguishmentOfDebt`	-	USD	Annual
Loss on extinguishment of debt	`GainsLossesOnExtinguishmentOfDebt`	$-1.26M	USD	Annual
Unrealized gain on change in fair value of senior secured convertible notes	`ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1`	-	USD	Annual
Unrealized gain on change in fair value of senior secured convertible notes	`ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1`	$1.97M	USD	Annual
Stock based compensation expense	`ShareBasedCompensation`	$1.13M	USD	Annual
Stock based compensation expense	`ShareBasedCompensation`	$1.36M	USD	Annual
Non-cash in process research and development	`ResearchAndDevelopmentInProcess`	-	USD	Annual
Non-cash in process research and development	`ResearchAndDevelopmentInProcess`	$251.42K	USD	Annual
Amortization of debt issuance costs	`AmortizationOfFinancingCosts`	$23.83K	USD	Annual
Amortization of debt issuance costs	`AmortizationOfFinancingCosts`	$1.48K	USD	Annual
Provision for bad debts	`ProvisionForDoubtfulAccounts`	$20.55K	USD	Annual
Provision for bad debts	`ProvisionForDoubtfulAccounts`	$7.62K	USD	Annual
Accounts receivable	`IncreaseDecreaseInAccountsReceivable`	$-638.34K	USD	Annual
Accounts receivable	`IncreaseDecreaseInAccountsReceivable`	$-1.08M	USD	Annual
Inventories	`IncreaseDecreaseInInventories`	$-78.74K	USD	Annual
Inventories	`IncreaseDecreaseInInventories`	$-105.10K	USD	Annual
Prepaid expenses, other current assets and deposits	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$-23.77K	USD	Annual
Prepaid expenses, other current assets and deposits	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$268.92K	USD	Annual
Accounts payable and accrued liabilities	`IncreaseDecreaseInAccountsPayableAndAccruedLiabilities`	$426.92K	USD	Annual
Accounts payable and accrued liabilities	`IncreaseDecreaseInAccountsPayableAndAccruedLiabilities`	$667.90K	USD	Annual
Deferred revenue	`IncreaseDecreaseInDeferredRevenues`	$1.50M	USD	Annual
Deferred revenue	`IncreaseDecreaseInDeferredRevenues`	$-727.92K	USD	Annual
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-6.92M	USD	Annual
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-6.86M	USD	Annual
Purchases of property and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$67.44K	USD	Annual
Purchases of property and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$266.01K	USD	Annual
Net cash used in investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-67.44K	USD	Annual
Net cash used in investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-266.01K	USD	Annual
Proceeds from secured convertible notes payable (including related parties of $550,000 and $1,185,000 for the years ended September 30, 2019 and 2018, respectively)	`ProceedsFromSecuredConvertibleNotesPayable`	$1.99M	USD	Annual
Proceeds from secured convertible notes payable (including related parties of $550,000 and $1,185,000 for the years ended September 30, 2019 and 2018, respectively)	`ProceedsFromSecuredConvertibleNotesPayable`	$1.65M	USD	Annual
Net proceeds from sale of common stock and warrants	`NetProceedsFromSaleOfCommonStockAndWarrants`	$4.23M	USD	Annual
Net proceeds from sale of common stock and warrants	`NetProceedsFromSaleOfCommonStockAndWarrants`	$2.46M	USD	Annual
Net proceeds from private placement	`ProceedsFromIssuanceOfPrivatePlacement`	-	USD	Annual
Net proceeds from private placement	`ProceedsFromIssuanceOfPrivatePlacement`	$402.38K	USD	Annual
Proceeds from exercise of warrants	`ProceedsFromIssuanceOfWarrants`	-	USD	Annual
Proceeds from exercise of warrants	`ProceedsFromIssuanceOfWarrants`	$987.50K	USD	Annual
Capitalized offering costs	`CapitalizedOfferingCostsClassifiedAsFinancingActivities`	-	USD	Annual
Capitalized offering costs	`CapitalizedOfferingCostsClassifiedAsFinancingActivities`	$-10.23K	USD	Annual
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$5.83M	USD	Annual
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$5.88M	USD	Annual
Net decrease in cash and cash equivalents	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$-1.30M	USD	Annual
Net decrease in cash and cash equivalents	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$-1.10M	USD	Annual
Cash and cash equivalents at beginning of year	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$2.96M	USD	Point-in-time
Cash and cash equivalents at beginning of year	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$558.99K	USD	Point-in-time
Cash and cash equivalents at beginning of year	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$1.66M	USD	Point-in-time
Cash and cash equivalents at end of year	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$2.96M	USD	Point-in-time
Cash and cash equivalents at end of year	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$558.99K	USD	Point-in-time
Cash and cash equivalents at end of year	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$1.66M	USD	Point-in-time
Cash paid during year for interest	`InterestPaid`	-	USD	Annual
Cash paid during year for interest	`InterestPaid`	-	USD	Annual
Cash paid during year for income taxes	`IncomeTaxesPaid`	-	USD	Annual
Cash paid during year for income taxes	`IncomeTaxesPaid`	-	USD	Annual
Public offering costs included in accounts payable and accrued liabilities	`OfferingCostsIncurredAndIncludedInAccountsPayable`	$64.85K	USD	Annual
Public offering costs included in accounts payable and accrued liabilities	`OfferingCostsIncurredAndIncludedInAccountsPayable`	$99.47K	USD	Annual
Deemed dividend-warrant repricing	`DeemedDividendWarrantRepricing`	-	USD	Annual
Deemed dividend-warrant repricing	`DeemedDividendWarrantRepricing`	$309.61K	USD	Annual
Interest paid in kind (related party of $98,752)	`PaidInKindInterest`	-	USD	Annual
Interest paid in kind (related party of $98,752)	`PaidInKindInterest`	$126.98K	USD	Annual
Impact of adoption of new accounting pronouncements included in accumulated deficit	`ImpactOfAdoptionOfNewAccountingPronouncementsIncludedInAccumulatedDeficitNonCashFinancingActivities`	-	USD	Annual
Impact of adoption of new accounting pronouncements included in accumulated deficit	`ImpactOfAdoptionOfNewAccountingPronouncementsIncludedInAccumulatedDeficitNonCashFinancingActivities`	$493.22K	USD	Annual
Warrants exercised cashlessly	`WarrantsExercisedCashlessly`	$100.00	USD	Annual
Warrants exercised cashlessly	`WarrantsExercisedCashlessly`	-	USD	Annual
Conversion of notes payable	`ConversionOfStockAmountConverted1`	-	USD	Annual
Conversion of notes payable	`ConversionOfStockAmountConverted1`	$1.44M	USD	Annual

Stockholders Equity 22 line items

Line Item	Tag	Value	Unit	Period
Balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$6.86M	USD	Point-in-time
Balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$754.50K	USD	Point-in-time
Balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$-848.50K	USD	Point-in-time
Balance (in shares)	`CommonStockSharesOutstanding`	1.20M	shares	Point-in-time
Balance (in shares)	`CommonStockSharesOutstanding`	752,802.00	shares	Point-in-time
Common stock issued in public offering, net of offering costs	`SharesIssuedInPublicOffering`	$2.46M	USD	Annual
Common stock issued in private placement, net of offering costs	`SharesIssuedInUnderwrittenPrivatePlacement`	$402.38K	USD	Annual
Common stock issued in private placement, net of offering costs	`SharesIssuedInUnderwrittenPrivatePlacement`	$4.23M	USD	Annual
Exercise of warrants	`StockIssuedDuringPeriodValueWarrantsExercised`	$987.50K	USD	Annual
Exercise of warrants cashlessly	`StockIssuedDuringPeriodValueWarrantsExercisesCashlessly`	-	USD	Annual
Common stock issued in secured convertible note conversion	`StockIssuedDuringPeriodValueConversionOfConvertibleSecurities`	$1.44M	USD	Annual
Investment in LineaRx, Inc.	`AdjustmentsToAdditionalPaidInCapitalInvestmentInSubsidiaries`	$113.13K	USD	Annual
Impact of adoption of new accounting pronouncements included in accumulated deficit	`ImpactOfAdoptionOfNewAccountingPronouncementsIncludedInAccumulatedDeficit`	$493.22K	USD	Annual
Stock based compensation expense	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$1.13M	USD	Annual
Stock based compensation expense	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$1.36M	USD	Annual
Net loss	`ProfitLoss`	$-8.63M	USD	Annual
Net loss	`ProfitLoss`	$-11.69M	USD	Annual
Balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$6.86M	USD	Point-in-time
Balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$754.50K	USD	Point-in-time
Balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$-848.50K	USD	Point-in-time
Balance (in shares)	`CommonStockSharesOutstanding`	1.20M	shares	Point-in-time
Balance (in shares)	`CommonStockSharesOutstanding`	752,802.00	shares	Point-in-time

Data is extracted from SEC EDGAR XBRL filings. Values shown are as reported in the filing.